DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for mixed germ cell tumor — screening already-approved drugs against its 20-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMixed germ cell tumor maps to a 20-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedSunitinibApproved drug
Structures already discussed alongside mixed germ cell tumor in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
KIT kinase domain — Sunitinib has a real, experimentally solved structure in complex with this target (PDB 3G0E, 1.6 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet b49drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3G0E · 1.6 Å · ligand Sunitinib (B49). Experimental structure, not a prediction.
What the evidence adds up to
Germ cell tumours are one of the few cancers for which highly effective treatment has been found over the past quarter-century, and a high proportion of patients are entered into large cooperative clinical trials. The tumours are diverse and management complex; referral to specialist oncology centres is considered necessary in all cases. A 2014 study from Saint Petersburg reports that a lack of awareness among young men and general practitioners often causes late medical aid appealability and potential diagnostic errors, and that reducing the time between a patient’s first contact and final diagnosis may contribute to earlier detection, reducing the amount of treatment and improving survival rates.
A 2015 case report describes a 14-year-old girl with a suprasellar mixed malignant germ cell tumour treated with complete surgical resection, chemotherapy, and radiation therapy. The authors state that, based on a literature review, platinum-based chemotherapy regimens combined with radiation therapy provide the best outcome in terms of survival rates, though they note this is controversial and debated. Twenty months post-treatment the patient was doing well and neurologically intact, but the authors caution that only time will tell the efficacy of that treatment plan.
A 2024 report on malignant mixed germ cell tumour of the ovary notes that the condition is incredibly uncommon in children. Early lesions are frequently asymptomatic; advanced tumours can cause vague abdominal pain and distention, and acute symptoms may result from rupture or twisting of the tumour. The prognosis is often favourable, and chemotherapy is frequently administered after conservative surgery that preserves reproductive function. The authors describe a case in an 8-year-old girl but give no numerical outcomes.
What is still missing are large, prospective trials that stratify patients by tumour subtype and location, standardised protocols for when to use surgery versus biopsy alone, and long-term follow-up data beyond single case reports. Funding for multicentre registries and randomised comparisons of platinum-based regimens with or without radiation would clarify which combinations truly improve survival without excessive toxicity.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
BMJ · 1992 · 7 citations · open access
Too many advisers, not enough aid.
AbstractThe most remarkable advance in therapeutic oncology during the past 10-15 years has been in the treatment of germ cell tumours. A high proportion of patients with these cancers are now entered into large cooperative clinical trials, which hold the key to improvements in management in the future. These tumours are diverse and their, management complex; referral to specialist oncology centres with the wide range of expertise necessary to treat these fascinating neoplasms should be considered in all cases.
Case Reports in Oncology · 2009 · 2 citations · open access
Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate
AbstractPatients with advanced germ cell tumors can be cured with cisplatin-based chemotherapy, but the outcome remains unsatisfactory for patients with relapsed disease, including those patients with refractory disease after bone marrow transplantation. Targeted therapies have changed the standard of care for many advanced solid tumors. We have identified, in the literature, potential targets for the treatment of refractory germ cell tumors, and applied to a patient with a refractory disease. We chose sunitinib for this purpose. To our knowledge, this is the first case to be treated with sunitinib, and we have found a promising activity.
Oncourology (Russian Society of Oncourologists) · 2014 · 1 citations · open access
IMPACT OF DELAYED PREHOSPITAL DIAGNOSIS ON THE RESULTS OF TREATMENT IN PATIENTS WITH GERMINOGENIC TESTICULAR TUMORS IN SAINT PETERSBURG
AbstractOver the past quarter-century germ cell tumors are one of the few cancers for which highly effective treatment is found. However there is a lack of awareness of young men and general practitioners about germ cell tumors which is often cause of late medical aid appealability and potential diagnostic errors. Reducing the time between patient's medical aid appealability and final diagnosis may contribute to the diagnostics of germ cell tumors in the early stages, reducing the amount of treatment and improving survival rates.
Research and reviews in pediatrics. · 2024 · 0 citations · open access
Malignant Mixed Germ Cell Tumor of the Ovary
AbstractAbstract The malignant mixed germ cell tumor (MGCT) is incredibly uncommon in children; however, it has been reported Since 1950. Early lesions are frequently asymptomatic, but advanced tumors can cause a number of symptoms, such as vague abdominal pain and distention. Acute symptoms could be due to the rupture or twisting of the tumor. The prognosis is often favorable, and chemotherapy is frequently administered after conservative surgery, which involves complete excision of the tumor and preservation of reproductive function. We describe a case of MGCT in an 8-year-old girl and highlight the diagnostic conundrum as well as the optimal management strategy.
Journal of Pediatric Neurology · 2015 · 0 citations
Suprasellar mixed malignant germ cell tumor: Case report and review of the literature
AbstractA 14-year-old girl with a suprasellar mixed malignant germ cell tumor was treated with complete surgical resection, chemotherapy, and radiation therapy. We performed a literature search to explore the current treatment options and prognosis of such a diagnosis. In reviewing the literature on mixed germ cell tumors, it appears that platinum-based chemotherapy regimens combined with radiation therapy provide the best outcome in terms of survival rates. Although controversial and debated, initial therapy should include surgical resection or a stereotactic biopsy when resection is not possible. By obtaining tissue for histopathology, one can tailor treatment plans accordingly and provide greater prognostic accuracy. In this case report, all three therapeutic modalities were used in the treatment of a mixed malignant germ cell tumor. Thus far, 20 months posttreatment, the patient is doing well and is neurologically intact, but diagnosis and treatment were relatively recent. Only time will tell the efficacy of this treatment plan.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
